This study investigates the potential role of Glycosyltransferases (GTs) in the glycosylation process and their association with malignant tumors. Specifically, the study focuses on PARP14, a member of GTs, and its potential as a target for tumors in the diagnosis and treatment of cervical cancer. To gather data, the study used somatic mutation data, gene expression data and clinical information from TCGA-CESE dataset as well as tissue samples from cervical cancer patients. Further verification was conducted through RT-qPCR and immunohistochemistry staining on cervical cancer tissues to confirm the expression of PARP14. The study utilized Kaplan-Meier for survival analysis of cervical cancer patient and found significant mutational abnormalities in GTs. The high frequency mutated gene was identified as PARP14. RT-qPCR revealed significantly higher mRNA expression of PARP14 compared to precancerous tissue. Using IHC combined with Kaplan-Meier,patients in the PARP14 high expression group had a better prognosis than the low expression group. The study identified PARP14 as a frequently mutated gene in cervical cancer and proposed its potential role in diagnosis and treatment.

本研究探讨了糖基转移酶 (GT) 在糖基化过程中的潜在作用及其与恶性肿瘤的关系。具体来说，该研究重点关注 GT 成员 PARP14 及其作为肿瘤靶点在宫颈癌诊断和治疗中的潜力。为了收集数据，该研究使用了 TCGA-CESE 数据集中的体细胞突变数据、基因表达数据和临床信息以及宫颈癌患者的组织样本。通过RT-qPCR和免疫组化染色对宫颈癌组织进行进一步验证，确认PARP14的表达。该研究利用Kaplan-Meier对宫颈癌患者进行生存分析，发现GTs存在显着的突变异常。高频突变基因被鉴定为PARP14。RT-qPCR 显示，与癌前组织相比，PARP14 的 mRNA 表达显着升高。IHC联合Kaplan-Meier检测发现PARP14高表达组患者预后优于低表达组。该研究将PARP14确定为宫颈癌中频繁突变的基因，并提出了其在诊断和治疗中的潜在作用。